Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant.

Wong G, Li MW, Howard K, Hua DK, Chapman JR, Bourke M, Turner R, Tong A, Craig JC.

Nephrol Dial Transplant. 2013 Apr;28(4):917-26. doi: 10.1093/ndt/gfs490. Epub 2012 Nov 25.

PMID:
23182812
2.

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.

Pharmacoeconomics. 2012 Jul 1;30(7):575-93. doi: 10.2165/11594990-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Nov 1;30(11):1096.

PMID:
22640174
3.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

4.

Screening of colorectal cancer.

Winawer SJ.

Surg Oncol Clin N Am. 2005 Oct;14(4):699-722. Review.

PMID:
16226687
5.

Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.

Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L, Grant A.

Health Technol Assess. 2006 Nov;10(45):1-141, iii-iv. Review.

6.

The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, D'Souza R, Welch K, Stein K.

Health Technol Assess. 2007 May;11(18):iii, xi-xiii, 1-167. Review.

7.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

8.

Cost-effectiveness of primary screening for CKD: a systematic review.

Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, Tangri N.

Am J Kidney Dis. 2014 May;63(5):789-97. doi: 10.1053/j.ajkd.2013.12.012. Epub 2014 Feb 12. Review.

PMID:
24529536
9.

Impact of comorbidity on colorectal cancer screening cost-effectiveness study in diabetic populations.

Dinh TA, Alperin P, Walter LC, Smith R.

J Gen Intern Med. 2012 Jun;27(6):730-8. doi: 10.1007/s11606-011-1972-6. Epub 2012 Jan 12. Review.

10.

Prevention or cure in times of crisis: the case of screening for colorectal cancer.

Carballo F, Muñoz-Navas M.

Rev Esp Enferm Dig. 2012 Oct-Nov;104(10):537-45. Review.

11.

Cost-effective treatment modalities for reducing morbidity associated with chronic kidney disease.

Ferguson TW, Tangri N, Rigatto C, Komenda P.

Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):243-52. doi: 10.1586/14737167.2015.1012069. Epub 2015 Feb 8. Review.

PMID:
25661187
12.

Economic evaluation of colorectal cancer (CRC) screening.

Cruzado J, Sánchez FI, Abellán JM, Pérez-Riquelme F, Carballo F.

Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):867-80. doi: 10.1016/j.bpg.2013.09.004. Epub 2013 Sep 27. Review.

PMID:
24182607
13.

The cost effectiveness of erythropoietin-stimulating agents for treating anemia in patients on dialysis: a systematic review.

Ferguson T, Xu Y, Gunasekara R, Lerner B, Macdonald K, Rigatto C, Tangri N, Komenda P.

Am J Nephrol. 2015;41(2):89-97. doi: 10.1159/000375541. Epub 2015 Feb 26. Review.

PMID:
25721696
14.

[Risk of cancer in patients following chronic dialysis and kidney graft].

Janus N, Launay-Vacher V, Ferrero JM, Thariat J.

Bull Cancer. 2012 Mar 1;99(3):285-93. doi: 10.1684/bdc.2012.1545. Review. French.

15.

Fifty years of dialysis in Africa: challenges and progress.

Barsoum RS, Khalil SS, Arogundade FA.

Am J Kidney Dis. 2015 Mar;65(3):502-12. doi: 10.1053/j.ajkd.2014.11.014. Epub 2015 Jan 17. Review.

PMID:
25600487
16.

Cardiovascular risk assessment in kidney transplantation.

Hart A, Weir MR, Kasiske BL.

Kidney Int. 2015 Mar;87(3):527-34. doi: 10.1038/ki.2014.335. Epub 2014 Oct 8. Review.

PMID:
25296093
17.

Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers.

Amiri FS.

Ren Fail. 2016;38(4):530-44. doi: 10.3109/0886022X.2016.1148523. Epub 2016 Feb 24. Review.

PMID:
26907957
18.

Chronic kidney disease and the aging population: World Kidney Day 2014.

Tonelli M, Riella M; World Kidney Day Steering Committee 2014..

Transplantation. 2014 Mar 15;97(5):490-3. doi: 10.1097/01.TP.0000441363.18856.d1. Review. No abstract available.

PMID:
24595115
19.

Assessment of patient eligibility for kidney transplant procedure.

Petrović D, Mijailović Z, Popovska B, Canović P.

Med Glas (Zenica). 2012 Aug;9(2):174-9. Review.

PMID:
22926347
20.

Chronic kidney disease and the aging population.

Tonelli M, Riella M.

J Nephrol. 2014 Feb;27(1):1-5. doi: 10.1007/s40620-014-0038-3. Review. No abstract available.

PMID:
24446349

Supplemental Content

Support Center